← board
PALI
Palisade Biodistress 5/10 · elevated risk$2.15+13%today-23% from 52w high
Immunology / Inflammation 2
Lead: Fibrostenotic Crohn's Disease · est. market ~$12B (approx, global)
Revenue
pre-revenue
Liquidity
$133M
Runway
10.7 yrs
Shares 1y
+1804%
Price & events
+15.9% over 6M
CatalystRating changeDilutionFinancingdashed = today
+12.9%
1D
+13.5%
1W
+10.6%
1M
-1.2%
3M
+12.3%
6M
+75.8%
1Y
-50.2%
2Y
-99.9%
5Y
-100.0%
All
Overview
- Market Cap
- $372.33M
- Volume
- 1.43M
- 52 Week Range
- $0.54 – $2.80
- Total Shares
- 173.58M
- Float Shares
- 132.72M
- Short %
- 18.52%
- % Held by Insiders
- 1.64%
- % Held by Institutions
- 93.84%
- RVOL
- 0.36x
- Beta
- 1.51
Pipeline stages · 1 programs
PALI-2108
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 2 trials · 0 upcoming
Catalyst news & presentations · 2
- 2026-03-30partnershipPALI-2108 · Master services agreement with Iterative Health to assist with Phase 2 study enrollment for ulcerative colitis.SEC 8-K
- 2025-10-09withdrawalCancelled special meeting and withdrew stockholder proposals due to lack of quorum.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $11 (+390% upside) · 8 analysts
- 2026-04-09Wolfe ResearchOutperform
- 2026-03-26HC Wainwright & Co.Buy
- 2026-02-25StifelBuy
- 2026-01-09B. Riley SecuritiesBuy
- 2025-12-30Clear StreetBuy
- 2025-12-29Piper SandlerOverweight
Competitors — Fibrostenotic Crohn's Disease
- none identified
Recent news
- 2026-07-23Oppenheimer Initiates Coverage on Palisade Bio With Outperform Rating, $8 Price Target - marketscreener.com
- 2026-07-23PALI Initiates Coverage On by Oppenheimer -- Rating 'Outperform' - GuruFocus
- 2026-07-10Form 4 Palisade Bio Inc For: 10 July By Investing.com - Investing.com Canada
- 2026-07-10Palisade Bio to Participate in the Leerink Partners Therapeutics Forum - GlobeNewswire
- 2026-07-10Palisade Bio leaders set to outline IBD drug plans at Boston forum - Stock Titan
- 2026-07-10Palisade Bio: A Unique MoA Targeting The UC And Crohn's Disease Markets - Seeking Alpha
- 2026-07-10Palisade Bio (PALI) director adds 45,000 shares through July open-market buys - Stock Titan
- 2026-07-10Palisade Bio director Robert Baltera Jr. purchases $88,698 in stock - Investing.com
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.